Department of Pharmacy, The Affiliated Hospital of Chengde Medical College, Chengde 067000, China.
Department of Functional Center, Chengde Medical College, Chengde 067000, China.
Dis Markers. 2021 Oct 8;2021:2571912. doi: 10.1155/2021/2571912. eCollection 2021.
Coronavirus disease 2019 (COVID-19) is highly contagious and continues to spread rapidly. However, there are no simple and timely laboratory techniques to determine the severity of COVID-19. In this meta-analysis, we assessed the potential of the neutrophil-lymphocyte ratio (NLR) as an indicator of severe versus nonsevere COVID-19 cases.
A search for studies on the NLR in severe and nonsevere COVID-19 cases published from January 1, 2020, to July 1, 2021, was conducted on the PubMed, EMBASE, and Cochrane Library databases. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio (DOR), and area under the curve (AUC) analyses were done on Stata 14.0 and Meta-disc 1.4 to assess the performance of the NLR.
Thirty studies, including 5570 patients, were analyzed. Of these, 1603 and 3967 patients had severe and nonsevere COVID-19, respectively. The overall sensitivity and specificity were 0.82 (95% confidence interval (CI), 0.77-0.87) and 0.77 (95% CI, 0.70-0.83), respectively; positive and negative correlation ratios were 3.6 (95% CI, 2.7-4.7) and 0.23 (95% CI, 0.17-0.30), respectively; DOR was 16 (95% CI, 10-24), and the AUC was 0.87 (95% CI, 0.84-0.90).
The NLR could accurately determine the severity of COVID-19 and can be used to identify patients with severe disease to guide clinical decision-making.
2019 年冠状病毒病（COVID-19）具有高度传染性，且仍在迅速传播。然而，目前尚无简单且及时的实验室技术来确定 COVID-19 的严重程度。在本荟萃分析中，我们评估了中性粒细胞与淋巴细胞比值（NLR）作为区分 COVID-19 重症与非重症病例的指标的潜力。
我们在 PubMed、EMBASE 和 Cochrane 图书馆数据库中对 2020 年 1 月 1 日至 2021 年 7 月 1 日期间发表的关于 NLR 在 COVID-19 重症与非重症病例中的研究进行了检索。我们使用 Stata 14.0 和 Meta-disc 1.4 进行汇总敏感性、特异性、阳性似然比、阴性似然比、诊断比值比（DOR）和曲线下面积（AUC）分析，以评估 NLR 的性能。
共分析了 30 项研究，共纳入 5570 例患者。其中，1603 例和 3967 例患者患有 COVID-19 重症和非重症。总体敏感性和特异性分别为 0.82（95%置信区间[CI]，0.77-0.87）和 0.77（95%CI，0.70-0.83），阳性和阴性似然比分别为 3.6（95%CI，2.7-4.7）和 0.23（95%CI，0.17-0.30），DOR 为 16（95%CI，10-24），AUC 为 0.87（95%CI，0.84-0.90）。
NLR 可准确判断 COVID-19 的严重程度，可用于识别重症患者，指导临床决策。
